206 related articles for article (PubMed ID: 27166661)
1. Monitoring of Epstein-Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab.
Fujieda M; Tsuruga K; Sato T; Kikuchi H; Tamaki W; Ishihara M; Yamamoto M; Oishi T; Tanaka H; Daibata M
Mod Rheumatol; 2017 Jan; 27(1):66-71. PubMed ID: 27166661
[TBL] [Abstract][Full Text] [Related]
2. Prospective monitoring of Epstein-Barr virus and other herpesviruses in patients with juvenile idiopathic arthritis treated with methotrexate and tocilizumab.
Kawada J; Iwata N; Kitagawa Y; Kimura H; Ito Y
Mod Rheumatol; 2012 Aug; 22(4):565-70. PubMed ID: 22057635
[TBL] [Abstract][Full Text] [Related]
3. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
[TBL] [Abstract][Full Text] [Related]
4. Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study.
Balandraud N; Texier G; Massy E; Muis-Pistor O; Martin M; Auger I; Guzian MC; Guis S; Pham T; Roudier J
PLoS One; 2017; 12(2):e0171623. PubMed ID: 28199343
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.
Feng WH; Cohen JI; Fischer S; Li L; Sneller M; Goldbach-Mansky R; Raab-Traub N; Delecluse HJ; Kenney SC
J Natl Cancer Inst; 2004 Nov; 96(22):1691-702. PubMed ID: 15547182
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of Epstein-Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritis.
Mourgues C; Henquell C; Tatar Z; Pereira B; Nourisson C; Tournadre A; Soubrier M; Couderc M
Joint Bone Spine; 2016 Jul; 83(4):412-5. PubMed ID: 26725744
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
[TBL] [Abstract][Full Text] [Related]
8. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
[TBL] [Abstract][Full Text] [Related]
9. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis.
Batu ED; Sönmez HE; Gülhan B; Arıcı ZS; Topaloğlu R; Bilginer Y
Turk J Pediatr; 2017; 59(1):6-12. PubMed ID: 29168357
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108
[TBL] [Abstract][Full Text] [Related]
11. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).
Ramanan AV; Dick AD; Benton D; Compeyrot-Lacassagne S; Dawoud D; Hardwick B; Hickey H; Hughes D; Jones A; Woo P; Edelsten C; Beresford MW;
Trials; 2014 Jan; 15():14. PubMed ID: 24405833
[TBL] [Abstract][Full Text] [Related]
12. Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies.
Miceli-Richard C; Gestermann N; Amiel C; Sellam J; Ittah M; Pavy S; Urrutia A; Girauld I; Carcelain G; Venet A; Mariette X
Arthritis Res Ther; 2009; 11(3):R77. PubMed ID: 19470150
[TBL] [Abstract][Full Text] [Related]
13. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
Machado SH; Xavier RM
Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841
[TBL] [Abstract][Full Text] [Related]
14. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjögren's syndrome: case series.
Dawson TM; Starkebaum G; Wood BL; Willkens RF; Gown AM
J Rheumatol; 2001 Jan; 28(1):47-53. PubMed ID: 11196542
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis.
Bulatović Ćalasan M; Vastert SJ; Scholman RC; Verweij F; Klein M; Wulffraat NM; Prakken BJ; van Wijk F
Rheumatology (Oxford); 2015 Sep; 54(9):1724-34. PubMed ID: 25877908
[TBL] [Abstract][Full Text] [Related]
17. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
[TBL] [Abstract][Full Text] [Related]
19. Serious adverse events in children with juvenile idiopathic arthritis and other rheumatic diseases on tocilizumab - a real-world experience.
Aeschlimann FA; Dumaine C; Wörner A; Mouy R; Wouters C; Melki I; Uettwiller F; Job-Deslandre C; Quartier P; Bader-Meunier B
Semin Arthritis Rheum; 2020 Aug; 50(4):744-748. PubMed ID: 32526594
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
